Sikich LLP is a business and technology consultancy who’s close to 1,500 team members provide advisory, consulting, and technology services to clients in life sciences, manufacturing, professional services, and other industries. The company’s life sciences practice spans the industry and supports more than 200 life sciences clients, including biotechnology and biopharmaceutical companies, CROs, and lab diagnostic companies. As a leading life science technology consultant, we can help you streamline operations and ensure compliance, allowing stakeholders to do what they do best: develop new medicines for patients who need them. | At Sikich, we empower life sciences organizations through strategic planning, regulatory expertise, and digital modernization. From inception to commercialization, we specialize in planning, regulatory, quality, and compliance, leveraging cutting-edge technologies like Oracle NetSuite, Honeywell’s TrackWise Digital, and Kneat’s solutions to streamline operations and accelerate innovation. Our tailored approach combines deep industry knowledge with advanced digital tools, ensuring compliance, enhancing efficiency, and reducing time-to-market for life-changing therapies. A focus on built in audit trails, roles-based control and automated reporting ensure compliance with FDA 21 CFR Part 11, SOX and EU Annex 11. With a commitment to precision, integrity, and transformation, we help companies navigate complex regulatory landscapes and embrace the future of life sciences with confidence. Plan smarter. Modernize faster. Innovate with impact.
SigutLabs s.r.o.
SigutLabs, a contract research organization (CRO) located in Prague, Czech Republic, helps businesses from small start-ups to pharmaceutical giants overcome their chemistry challenges. Our agile PhD chemists specialize in custom synthesis, scale-up, and contract research across organic, bioorganic, and medicinal chemistry, with a focus on nucleotide and nucleoside chemistry, ADC linkers, and advanced applications. We excel at developing novel synthetic routes for undescribed compounds and custom synthesis of known molecules, also offering dedicated FTE chemists. We have a lean team of up to 10 employees with every chemist holding a PhD degree, which is an industry-leading scientific staff ratio. All our experts studied at prestigious universities and have extensive experience in organic and medicinal chemistry from top international institutions. Our cutting-edge labs prioritize a sustainable future with eco-friendly practices and invest in top-tier equipment to handle your most complex projects. Products from our inventory are available for purchase through our e-shop, ensuring super-fast and secure delivery worldwide. Founded in 2011, SigutLabs has grown from a small lab to a partner of choice for leading pharmaceutical and Silicon Valley companies. We played a major role in the fight against COVID-19 by developing a new synthetic pathway of remdesivir for research in just four months, and were recognized for our achievements with the 2023 Company of the Year award (Central Bohemia region). Fueled by a vision to build on the legacy of Czech chemistry, exemplified by Prof. Antonín Holý and his groundbreaking molecule tenofovir, we aim to re-establish the Czech Republic’s position on the global chemistry map. We can tackle your toughest challenges with our team’s diverse chemistry experience, including: ADC linkers Heterocyclic chemistry Palladium-catalyzed reactions Organometallic chemistry Nucleoside/nucleotide chemistry Fluorine chemistry Photochemistry Supramolecular chemistry Total synthesis of natural products Modification of enzyme substrates/inhibitors Visit our website at www.sigutlabs.com to see how SigutLabs frees hands, saves costs, and accelerates your projects with our outsourced chemistry expertise. Follow us on LinkedIn to see the latest news. | x
Shanghai Taichu Biotechnology Co., Ltd.
Taichu group was founded in 2020, providing contract research, development and manufacturing services to pharmaceutical and biotech companies. Our service platforms include early discovery and design of complex antibodies such as multispecific antibodies, nanobodies, fusion proteins etc. Our GLP- and AAALAC- certified animal facility provides preclinical studies (PK/PD), safety evaluation (Toxicology) for a various modality of drug candidates, such as small molecules, biologics, ADC, CGT products, and RNAi, ASO, mRNA molecules. For development and manufacturing of complex antibodies, our CDMO (Tarlead) has experienced teams, well-established laboratories and facility for process development, drug substance production and drug product manufacturing, ready to meet your needs and timelines. | Taichu Group is a biotechology enterprise with a core advantage in “CRO+CDMO integrated services”, providing end-to-end solutions for global innovative drug development from early discovery through preclinical research. Headquartered in Shanghai’s Lingang Special Area, the Group operates through its subsidiaries: Taichu Bio (Pre-Clinical Research), AceMab Ltd (Antibody Discovery & Design), Tarlead Biologics (Biologics Development & Manufacturing), TJR Bio (Nucleic Acid Drug Process & Manufacturing), and Taichu (Shenzhen) (Innovative Therapeutic Development Advisory). Guided by the philosophy “Advocate of Ethics and Integrity, Quest for Verity”, we streamline R&D workflows and accelerate therapeutic advancement for global partners. Our synergistic service model bridges key gaps between discovery and commercialization, reinforcing our role as a strategic enabler in the biopharmaceutical innovation value chain.
Shanghai OPM Biosciences Co., Ltd
OPM Biosciences (Stock Code: 688293) is a leading provider of Cell Culture Media (CCM) and CDMO (Contract Development and Manufacturing Organization) services. We offer an integrated solution to meet the needs of biopharmaceutical companies worldwide. OPM was established in 2013 dedicated to total cell culture solution development, which has resulted in our fast growth. We are proud to be the first listed CCM company in China and committed to being a total solution provider in biologics development. Our management system is certified to ISO9001:2015 by TÜV NORD. We have four fully cGMP-compliant plants, covering an overall area of 18,000m². Currently, we are constructing a new 30,000m² headquarters to meet the growing demand for our products and services. OPM is becoming a strategic partner of biopharmaceutical companies worldwide, and our dedication to quality and innovation ensures that we continue to be a trusted partner in the industry. Our CCM solutions are renowned for their innovative chemically-defined/serum-free media design and manufacturing. We offer a range of products and services, including proprietary commercial media, customized formulations, and OEM solutions for our clients’ unique cell lines. Our exceptional performance has established us as the preferred supplier for over 230 biologics (IND or BLA) worldwide. In addition, OPM’s CDMO services provide efficient End-to-End solutions for biotherapeutic protein development and manufacturing. Our cGMP-compliant facilities support all stages of biologics development, from antibody discovery to IND and BLA manufacturing up to 2000L. Our dedicated team of experienced scientists is committed to excellence and has contributed to the development of over 200 biologics, supporting global clients in achieving successful IND applications with the FDA and NMPA.
SCIWIN Laboratories Co., Ltd
Custom Organic Synthesis Biopharmaceutical Providing CRO & CMO services for API manufacturers and new drug companies ADC-Novel linker-Payloads Organic synthesis-Small molecule & macromolecule Custom synthesis-reference & impurity standard Technology transfer-Lab to GMP manufacturer Professional Custom Synthesis Services to Meet Your Drug Development Needs SCIWINLAB specializes in providing high-quality custom synthesis services, covering synthesis and process development from small-scale (milligram-level) to large-scale (kilogram-level) production. Our R&D team possesses 10 to 20 years of GMP experience in the pharmaceutical industry, excelling in process optimization and ensuring smooth technology transfer to GMP facilities for scale-up production. With our expertise in organic synthesis, we are committed to delivering reliable and efficient solutions to our clients. To date, we have successfully assisted multiple pharmaceutical companies in transferring technology to GMP facilities, completing the scale-up of five products, and accelerating their market entry. | Custom Organic Synthesis Providing CRO Contract Manufacturing Organization) & CMO (Contract Development and Manufacturing Organization) services for API (Active Pharmaceutical Ingredients) manufacturers and new drug companies ADC-Novel linker-Payloads Organic synthesis-Small molecule & macromolecule Custom synthesis-reference & impurity standard Technology transfer-Lab to GMP manufacturer
SanaClis CRO
SanaClis CRO – Founded in 2000, SanaClis is a full-service global CRO with strong in-house clinical supply chain, logistics, and sourcing capabilities. We support clinical trials worldwide across the full study lifecycle and can operate as either a full-service or functional service provider, depending on sponsor needs. We have delivered clinical trial projects for sponsors ranging from virtual biotech to top 10 pharmaceutical companies, combining operational rigor with responsive execution and a focus on quality and predictable delivery. SanaClis provides CRO and clinical supply chain services across all therapeutic areas, with coverage across Europe (including the UK), USA (Americas) and Asia. We also bring deep operational experience in Central and Eastern Europe (CEE), supporting strong patient access and reliable site performance. To enable global distribution, SanaClis operates a network of privately owned, GMP- and GDP-certified depots strategically located worldwide. Our facilities support ambient and cold-chain storage, as well as packaging, labeling, and distribution services to protect product integrity throughout the IMP cold chain. CRO Services: Project Management, Clinical Monitoring, Site Management, Regulatory, Medical Writing, Data Management, Biostatistics, Pharmacovigilance, Medical Monitoring, Quality Management, Decentralized Trials. Clinical Supply Chain Services: Storage and Distribution, Secondary Packaging and Labelling, Global Strategic Sourcing, Qualified Person Services, Customs and Brokerage, SIMS – Inventory Management, Direct to Patient Services. Please reach out to Matt Delaney, Vice President of Business Development for the Americas region, email: matt.delaney@sanaclis.com or by phone at: 1 805 798-0060. Matt resides in San Diego, Ca.
RudaCure
RudaCure is a clinical-stage biotechnology company dedicated to developing innovative treatments for incurable diseases with sensory based disorders and high unmet medical needs. | RudaCure is a clinical-staged biotech company dedicated to developing innovative first-in-class treatments for incurable diseases with sensory based disorders and high unmet medical needs. RudaCure’s multi-indication pipeline include treatments for dry eye and chronic pain.
Rivia AG
x | RIVIA is the first Trial Intelligence platform with Agentic AI tools for modern sponsors. It brings all clinical and operational data into one single view, giving sponsors real-time control of the clinical development and saving up to 30% of the monitoring costs. All-in-one. All in real time. No more waiting on the CROs.
Richmond Pharmacology
Richmond Pharmacology is a leading UK-based contract research organisation (CRO) providing comprehensive clinical research services from First-in-Human (FIH) and First-in-Patient (FIP) through to Phase III studies. For over two decades, we have partnered with pharmaceutical and biotechnology companies globally — particularly across the United States, Europe, and Japan — to deliver faster answers and empower smarter development decisions. Operating from a state-of-the-art clinical pharmacology unit in London, we integrate real-world clinical expertise, regulatory foresight, and operational excellence to support the successful delivery of complex clinical development programmes. Faster Answers for Smarter Decisions At Richmond Pharmacology, “Faster Answers” is our guiding principle. Through a combination of expert-led study design, agile operational models, and strategic regulatory insight, we enable sponsors to generate high-quality data earlier, accelerating programme timelines and reducing development risk. Our Core Expertise Includes: First-in-Human (FIH), First-in-Patient (FIP), and Clinical Development up to Phase III: Extensive experience managing trials from initial dosing through proof-of-concept and pivotal Phase III studies, across a broad range of therapeutic areas. Gene Editing and Gene Silencing Studies: Richmond Pharmacology is proud to support cutting-edge research in advanced therapeutic modalities, including CRISPR-Cas9 genome editing and RNA interference (RNAi)-based gene silencing, helping innovators bring transformative medicines to patients faster. Patient and Healthy Volunteer Studies: Our work spans both healthy volunteer and patient-focused research, with a strategic emphasis towards increasing patient-centric trials to better reflect real-world treatment needs. Rare and Orphan Disease Trials: We are recognised for our ability to design and conduct trials for rare and ultra-rare conditions, navigating recruitment and operational complexities with sensitivity and precision. Bridging Studies: Richmond Pharmacology is a leader in Japanese–European bridging studies, providing critical data to support global strategies. Cardiovascular, Metabolic, and Central Nervous System (CNS) Disorders: Specialist expertise in diseases such as cardiovascular disease (CVD), chronic kidney disease (CKD), hyperlipidaemia, non-alcoholic steatohepatitis (NASH), diabetes, and neurodegenerative or psychiatric disorders. Complex and Adaptive Trial Designs: Expertise in designing seamless adaptive protocols, umbrella trials, and novel methodologies that optimise development pathways while preserving scientific and regulatory integrity. Patient and Public Involvement (PPI): We embed Patient and Public Involvement across study planning and execution, ensuring trial designs are informed by patient perspectives to enhance engagement, experience, and outcomes. Regulatory Strategy and Scientific Consultancy: Richmond Pharmacology provides scientific and regulatory consultancy services, guiding sponsors through regulatory interactions and optimising study designs for approvals in the UK, US, and Europe. Why Partner with Richmond Pharmacology? Our experienced team, operational flexibility, and focus on scientific excellence make Richmond Pharmacology a trusted partner for companies seeking faster, smarter clinical development. Whether advancing a novel genetic therapy, accelerating a rare disease treatment, or bridging critical data across regions, we provide the solutions needed to move innovative therapies forward. For more information, please visit www.richmondpharmacology.com